Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPICURE (PIPAC-OPC6): PIPAC plus curative minimally invasive gastrectomy in high-risk gastric cancer
2024-516194-76-00Phase 2Authorised
- Sponsor
- University Hospital Odense
- Start
- Jun 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of doxorubicin and cisplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by University Hospital Odense. Primary endpoint: Peritoneal disease-free survival. Planned start Jun 2025; status: authorised.
02
Drugs
doxorubicincisplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-516194-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516194-76-00.